China
Africa
Explore chapters and articles related to this topic
Gaps and Future Considerations for Development of Transdermal and Topical Delivery Systems
Published in Tapash K. Ghosh, Dermal Drug Delivery, 2020
The pressure sensitive adhesives (PSA) used in transdermal systems must be able to deform under slight pressure; adhesion occurs by applying pressure which induces a liquid-like flow of the PSA and wetting of the skin surface. Although the fluidity of the adhesive is required for adhesion, it can cause a quality issue commonly known as cold flow. Cold flow is the creep or oozing of the adhesive matrix beyond the parameter of the backing membrane. The presence of cold flow may result in increased or unintentional exposure to the drug substance, make it difficult for the patient to remove the transdermal delivery system from the pouch and/or release liner, and cause a “tacky” ring around the perimeter.8
Topical creams of piperine loaded lipid nanocarriers for management of atopic dermatitis: development, characterization, and in vivo investigation using BALB/c mice model
Published in Journal of Liposome Research, 2022
Pravin Kumar, Dinesh Kumar Sharma, Mahendra Singh Ashawat
After the permeation study, the diffusion cell was dismounted after 24 h; the skin was removed and washed with saline. After washing, the piperine deposited on the skin surface was stripped by a pressure-sensitive adhesive tape. The piperine in the tape represents the deposition in the stratum corneum (Jia et al.2017). Then the skin was chopped using a sharp surgical blade to extract the amount of piperine deposited in the epidermis and dermis. The adhesive tape and chopped skin were soaked separately in 10 ml of ethanol in a volumetric flask. The flasks were kept overnight and then sonicated for complete drug extraction (Kaur et al.2018). The solutions were filtered and filtrates were analyzed by HPLC to estimate the retention (%) of piperine in different skin layers.
Ketamine-polymer based drug delivery system for prolonged analgesia: recent advances, challenges and future prospects
Published in Expert Opinion on Drug Delivery, 2021
Surabhi Singh, Amit Kumar, Gaurav Mittal
A polymeric transdermal drug-in-reservoir skin patch based on ketamine has been designed by Tang et al. [79] comprising a backing layer, a reservoir layer, a rate-controlling membrane, an adhesive layer, and a release liner. The backing layer was made up of polyesters such as Scotchpak 9736 or polyurethane film, or polyethylene film such as CoTran 9720. The reservoir layer includes ketamine in combination with gel forming agents such as hydroxypropylcellulose (HPC) or hydroxypropyl methyl cellulose (HPMC) or polyvinyl pyrrolidone (PVP such as BASF’s Kollidon) or polyacrylic acid (such as Carbopol) or sodium CMC (carboxyl methyl cellulose), or a combination. The adhesive layer comprised a pressure sensitive adhesive, for example, a polyisobutylene (PIB) adhesive or a silicone polymer adhesive, or an acrylate copolymer adhesive. The rate-controlling membrane was a microporous membrane of polypropylene film or polyethylene-vinyl-acetate (EVA) film, or a combination. The sustained release profile of ketamine from transdermal drug delivery device was monitored in vitro using human cadaver skin and the results indicated that tunable ketamine release could be achieved varying from 18 h to 7 days.
Investigating the influences of intermolecular interactions on viscoelastic performance of pressure-sensitive adhesive by FT–IR spectroscopy and molecular modeling
Published in Drug Development and Industrial Pharmacy, 2020
Transdermal drug delivery system (TDDS) is developed as a successful drug delivery preparation in the past decades [1], which is applied to skin to deliver drug into the local tissue or systemic circulation. Drug-in-adhesive (DIA) type patch is a common design due to the advantages of simple and stable structure, and good patient compliance [2]. Pressure-sensitive adhesive (PSA) used in TDDS is critical to safety, efficacy, and quality of the DIA type products [3], which not only acts as a drug reservoir but also provides adhesion force for the patch and determines the duration of patch administration [4]. Unfortunately, United States Food and Drug Administration (FDA) received numerous reports about the adhesion issues of transdermal patch in the Drug Quality Reporting System (DQRS) [3], including adhesion force lacking, patch displacement, and ‘dark ring’ phenomenon. It will hinder the efficiency and accuracy of patch administration.